JP2024177330A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024177330A5 JP2024177330A5 JP2024173232A JP2024173232A JP2024177330A5 JP 2024177330 A5 JP2024177330 A5 JP 2024177330A5 JP 2024173232 A JP2024173232 A JP 2024173232A JP 2024173232 A JP2024173232 A JP 2024173232A JP 2024177330 A5 JP2024177330 A5 JP 2024177330A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- lymphoma
- antibody
- cell
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical group 0.000 claims 24
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 15
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 230000003211 malignant effect Effects 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 208000003950 B-cell lymphoma Diseases 0.000 claims 6
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 5
- 238000006467 substitution reaction Methods 0.000 claims 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 4
- 208000016778 CD4+/CD56+ hematodermic neoplasm Diseases 0.000 claims 4
- 208000017604 Hodgkin disease Diseases 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 4
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 4
- 208000034578 Multiple myelomas Diseases 0.000 claims 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 4
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 4
- 125000002252 acyl group Chemical group 0.000 claims 4
- 201000003444 follicular lymphoma Diseases 0.000 claims 4
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims 4
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 4
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 239000002254 cytotoxic agent Substances 0.000 claims 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 208000017726 ALK-positive large B-cell lymphoma Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 206010002412 Angiocentric lymphomas Diseases 0.000 claims 2
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims 2
- 206010003908 B-cell small lymphocytic lymphoma Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000005024 Castleman disease Diseases 0.000 claims 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 2
- 208000016403 Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 241001502974 Human gammaherpesvirus 8 Species 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 201000003791 MALT lymphoma Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 claims 2
- 208000019569 Nodular lymphocyte predominant Hodgkin lymphoma Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 208000007452 Plasmacytoma Diseases 0.000 claims 2
- 206010036524 Precursor B-lymphoblastic lymphomas Diseases 0.000 claims 2
- 206010065857 Primary Effusion Lymphoma Diseases 0.000 claims 2
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 claims 2
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims 2
- 239000005700 Putrescine Substances 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 208000011778 T-cell/histiocyte rich large B cell lymphoma Diseases 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000013056 classic Hodgkin lymphoma Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 210000003141 lower extremity Anatomy 0.000 claims 2
- 208000006116 lymphomatoid granulomatosis Diseases 0.000 claims 2
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000025113 myeloid leukemia Diseases 0.000 claims 2
- 208000031223 plasma cell leukemia Diseases 0.000 claims 2
- 208000010626 plasma cell neoplasm Diseases 0.000 claims 2
- 208000007525 plasmablastic lymphoma Diseases 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 2
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims 2
- 201000006845 reticulosarcoma Diseases 0.000 claims 2
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 2
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 230000005751 tumor progression Effects 0.000 claims 2
- GTDUJUNPLJULJB-FJXQXJEOSA-N (2S)-2-acetamido-6-aminohexanoic acid 3-aminopropanoic acid Chemical compound NCCC(O)=O.CC(=O)N[C@@H](CCCCN)C(O)=O GTDUJUNPLJULJB-FJXQXJEOSA-N 0.000 claims 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- STWGYALNEBWQQL-FJXQXJEOSA-N NCC(O)=O.CC(=O)N[C@H](C(O)=O)CCCCN Chemical compound NCC(O)=O.CC(=O)N[C@H](C(O)=O)CCCCN STWGYALNEBWQQL-FJXQXJEOSA-N 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 108060008539 Transglutaminase Proteins 0.000 claims 1
- 229960002684 aminocaproic acid Drugs 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 229920001222 biopolymer Polymers 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- 230000021615 conjugation Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012216 imaging agent Substances 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 102000003601 transglutaminase Human genes 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762577922P | 2017-10-27 | 2017-10-27 | |
| US62/577,922 | 2017-10-27 | ||
| JP2020523378A JP7324749B2 (ja) | 2017-10-27 | 2018-10-16 | Ｃｄ１２３に特異的な抗体および抗体－薬物コンジュゲートならびにその使用 |
| PCT/IB2018/058013 WO2019082020A1 (en) | 2017-10-27 | 2018-10-16 | ANTIBODIES AND CONJUGATES CD123-SPECIFIC ANTIBODIES AND USES THEREOF |
| JP2023124386A JP2023139267A (ja) | 2017-10-27 | 2023-07-31 | Ｃｄ１２３に特異的な抗体および抗体－薬物コンジュゲートならびにその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023124386A Division JP2023139267A (ja) | 2017-10-27 | 2023-07-31 | Ｃｄ１２３に特異的な抗体および抗体－薬物コンジュゲートならびにその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024177330A JP2024177330A (ja) | 2024-12-19 |
| JP2024177330A5 true JP2024177330A5 (enExample) | 2025-01-29 |
Family
ID=64109968
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020523378A Active JP7324749B2 (ja) | 2017-10-27 | 2018-10-16 | Ｃｄ１２３に特異的な抗体および抗体－薬物コンジュゲートならびにその使用 |
| JP2023124386A Pending JP2023139267A (ja) | 2017-10-27 | 2023-07-31 | Ｃｄ１２３に特異的な抗体および抗体－薬物コンジュゲートならびにその使用 |
| JP2024173232A Pending JP2024177330A (ja) | 2017-10-27 | 2024-10-02 | Ｃｄ１２３に特異的な抗体および抗体－薬物コンジュゲートならびにその使用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020523378A Active JP7324749B2 (ja) | 2017-10-27 | 2018-10-16 | Ｃｄ１２３に特異的な抗体および抗体－薬物コンジュゲートならびにその使用 |
| JP2023124386A Pending JP2023139267A (ja) | 2017-10-27 | 2023-07-31 | Ｃｄ１２３に特異的な抗体および抗体－薬物コンジュゲートならびにその使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11613581B2 (enExample) |
| EP (1) | EP3700929A1 (enExample) |
| JP (3) | JP7324749B2 (enExample) |
| KR (1) | KR102363746B1 (enExample) |
| CN (2) | CN111556876B (enExample) |
| AU (1) | AU2018357221B2 (enExample) |
| BR (1) | BR112020008127A2 (enExample) |
| CA (2) | CA3079788C (enExample) |
| CO (1) | CO2020005347A2 (enExample) |
| IL (1) | IL274095B2 (enExample) |
| MX (1) | MX2020004381A (enExample) |
| PE (1) | PE20201255A1 (enExample) |
| PH (1) | PH12020550596A1 (enExample) |
| SA (1) | SA520411849B1 (enExample) |
| SG (1) | SG11202003246WA (enExample) |
| TW (2) | TWI718427B (enExample) |
| WO (1) | WO2019082020A1 (enExample) |
| ZA (1) | ZA202002207B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3012994C (en) * | 2013-07-31 | 2020-10-20 | Rinat Neuroscience Corp. | Engineered polypeptide conjugates |
| EP4467565A3 (en) | 2016-12-21 | 2025-03-12 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| NZ762376A (en) | 2017-09-19 | 2022-08-26 | Scherrer Inst Paul | Transglutaminase conjugation method and linker |
| CA3079788C (en) | 2017-10-27 | 2023-09-05 | Pfizer Inc. | Antibodies and antibody-drug conjugates specific for cd123 and uses thereof |
| SE544015C2 (en) * | 2019-06-18 | 2021-11-02 | Tx Medic Ab | Allogenic car-t cell therapy |
| EP4114852A1 (en) * | 2020-03-03 | 2023-01-11 | Sutro Biopharma, Inc. | Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use |
| CN113563470B (zh) * | 2020-04-29 | 2023-02-10 | 广州昂科免疫生物技术有限公司 | 结合tigit抗原的抗体及其制备方法与应用 |
| AU2021366341A1 (en) | 2020-10-25 | 2023-06-22 | Araris Biotech Ag | Means and methods for producing antibody-linker conjugates |
| EP4346882A1 (en) * | 2021-05-26 | 2024-04-10 | Oxford BioTherapeutics Ltd | Pharmaceutical combination comprising an anti-cd205 antibody and an immune checkpoint inhibitor |
| CN116018351A (zh) * | 2021-08-16 | 2023-04-25 | 上海优替济生生物医药有限公司 | 靶向cd123的抗体、嵌合抗原受体及其用途 |
| JP2024539989A (ja) * | 2021-10-25 | 2024-10-31 | アラリス バイオテック アーゲー | 抗体－リンカーコンジュゲートを生成する方法 |
| TW202423485A (zh) * | 2022-12-08 | 2024-06-16 | 美商伊繆諾金股份有限公司 | 包含抗cd123抗體-藥物結合物及抗cd47抗體之治療組合 |
| WO2025227361A1 (en) * | 2024-04-30 | 2025-11-06 | Wuxi Xdc (Shanghai) Co., Ltd. | Process for preparing a composition of antibody-drug conjugates (adcs) with high d4 content |
| CN118416247A (zh) * | 2024-04-30 | 2024-08-02 | 上海药明合联生物技术有限公司 | 用于制备具有高d4含量的抗体-药物缀合物（adc）组合物的方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| EP1158997A2 (en) | 1999-03-09 | 2001-12-05 | University Of Southern California | Method of promoting myocyte proliferation and myocardial tissue repair |
| WO2008127735A1 (en) | 2007-04-13 | 2008-10-23 | Stemline Therapeutics, Inc. | Il3ralpha antibody conjugates and uses thereof |
| PL2426148T3 (pl) * | 2009-04-27 | 2016-01-29 | Kyowa Hakko Kirin Co Ltd | Przeciwciało anty-IL-3RA do stosowania w leczeniu nowotworu krwi |
| US9676871B2 (en) * | 2010-11-05 | 2017-06-13 | Pfizer Inc. | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| DK2699264T3 (en) | 2011-04-20 | 2018-06-25 | Medimmune Llc | ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1 |
| EP2780039B9 (en) | 2011-11-17 | 2018-04-18 | Pfizer Inc | Cytotoxic peptides and antibody drug conjugates thereof |
| CA3012994C (en) | 2013-07-31 | 2020-10-20 | Rinat Neuroscience Corp. | Engineered polypeptide conjugates |
| BR112016016490B1 (pt) * | 2014-01-27 | 2022-11-29 | Pfizer Inc | Compostos de agentes citotóxicos bifuncionais, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos |
| KR102430829B1 (ko) | 2014-04-25 | 2022-08-09 | 리나트 뉴로사이언스 코프. | 약물이 고도로 로딩된 항체-약물 접합체 |
| JO3568B1 (ar) * | 2014-09-05 | 2020-07-05 | Janssen Pharmaceutica Nv | عوامل ربط cd123 واستخداماتها |
| TN2018000324A1 (en) * | 2015-01-23 | 2020-01-16 | Sanofi Sa | ANTl-CD3 ANTIBODIES, ANTl-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO CD3 AND/OR CD123 |
| TW201709932A (zh) * | 2015-06-12 | 2017-03-16 | 西雅圖遺傳學公司 | Ｃｄ１２３抗體及其共軛物 |
| CN107921146A (zh) * | 2015-06-23 | 2018-04-17 | 拜耳医药股份有限公司 | 纺锤体驱动蛋白(ksp)抑制剂与抗‑cd123的抗体的抗体药物缀合物(adc) |
| LT3313884T (lt) * | 2015-06-29 | 2021-03-10 | Immunogen, Inc. | Anti-cd123 antikūnai, konjugatai ir jų dariniai |
| US11976121B2 (en) * | 2017-07-20 | 2024-05-07 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | CD123-binding chimeric antigen receptors |
| CA3079788C (en) | 2017-10-27 | 2023-09-05 | Pfizer Inc. | Antibodies and antibody-drug conjugates specific for cd123 and uses thereof |
-
2018
- 2018-10-16 CA CA3079788A patent/CA3079788C/en active Active
- 2018-10-16 EP EP18797140.3A patent/EP3700929A1/en active Pending
- 2018-10-16 CN CN201880069901.2A patent/CN111556876B/zh active Active
- 2018-10-16 IL IL274095A patent/IL274095B2/en unknown
- 2018-10-16 CA CA3205442A patent/CA3205442A1/en active Pending
- 2018-10-16 CN CN202411219753.1A patent/CN119119272A/zh active Pending
- 2018-10-16 JP JP2020523378A patent/JP7324749B2/ja active Active
- 2018-10-16 US US16/758,124 patent/US11613581B2/en active Active
- 2018-10-16 AU AU2018357221A patent/AU2018357221B2/en active Active
- 2018-10-16 WO PCT/IB2018/058013 patent/WO2019082020A1/en not_active Ceased
- 2018-10-16 MX MX2020004381A patent/MX2020004381A/es unknown
- 2018-10-16 KR KR1020207014653A patent/KR102363746B1/ko active Active
- 2018-10-16 BR BR112020008127-2A patent/BR112020008127A2/pt unknown
- 2018-10-16 SG SG11202003246WA patent/SG11202003246WA/en unknown
- 2018-10-16 PE PE2020000682A patent/PE20201255A1/es unknown
- 2018-10-24 TW TW107137519A patent/TWI718427B/zh active
- 2018-10-24 TW TW110103347A patent/TWI793513B/zh active
-
2020
- 2020-04-27 SA SA520411849A patent/SA520411849B1/ar unknown
- 2020-04-28 CO CONC2020/0005347A patent/CO2020005347A2/es unknown
- 2020-04-29 PH PH12020550596A patent/PH12020550596A1/en unknown
- 2020-05-04 ZA ZA2020/02207A patent/ZA202002207B/en unknown
-
2023
- 2023-03-08 US US18/180,704 patent/US20230357417A1/en not_active Abandoned
- 2023-07-31 JP JP2023124386A patent/JP2023139267A/ja active Pending
-
2024
- 2024-10-02 JP JP2024173232A patent/JP2024177330A/ja active Pending
- 2024-12-03 US US18/967,173 patent/US20250154270A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024177330A5 (enExample) | ||
| IL274095B1 (en) | Antibodies and antibody-drug conjugates specific for cd123 and uses thereof | |
| JP2021500055A5 (enExample) | ||
| KR20220130160A (ko) | 에리불린 유도체의 약물 접합체, 이를 제조하기 위한 방법 및 의료분야에서 이의 용도 | |
| TWI780104B (zh) | 抗ｇｐｒ２０抗體及抗ｇｐｒ２０抗體-藥物結合物、以及其製造方法及用途 | |
| Wahl et al. | The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin’s disease | |
| JP3600617B2 (ja) | ヒト上皮細胞成長因子レセプターに特異的なモノクローナル抗体及びそれを用いた治療剤 | |
| WO2021052402A1 (zh) | 一种喜树碱衍生物及其偶联物 | |
| US12168060B2 (en) | Antibody-drug conjugates comprising anti-B7-H3 antibodies | |
| CN105198997B (zh) | Cd37免疫治疗剂及其与双功能化学治疗剂的联合 | |
| EP4591941A2 (en) | Bispecific antibody and use thereof | |
| Litvak-Greenfeld et al. | Risks and untoward toxicities of antibody-based immunoconjugates | |
| TWI867066B (zh) | 靶向flt3之抗體及其用途 | |
| JP2022536685A (ja) | 免疫調節物質抗体薬物コンジュゲートおよびその使用 | |
| CN102659947A (zh) | 新型抗cd98抗体 | |
| TW202330604A (zh) | 靶向ｂａｆｆ—ｒ的抗體及其用途 | |
| TW201442728A (zh) | 新穎抗體結合物及其用途 | |
| KR20110096550A (ko) | Ｃｄ３８을 특이적으로 인식하는 항체 및 멜팔란을 함유하는 항종양 조합물 | |
| JP2012510463A (ja) | Ｃｄ３８を特異的に認識する抗体とシタラビンを含有する抗腫瘍性組合せ剤 | |
| Younes | CD30-targeted antibody therapy | |
| Mehta et al. | Development and integration of antibody–drug conjugate in non-Hodgkin lymphoma | |
| Lorenzo et al. | From immunotoxins to immunoRNases | |
| CN118345101A (zh) | 用于用抗bcma免疫治疗来治疗癌症的组合物和方法 | |
| CN111093701A (zh) | 含有抗globo h抗体的抗体药物偶联物及其用途 | |
| KR20250137203A (ko) | 항체 약물 접합체 |